Drug Resistance

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Drug Resistance is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

11/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed4 · 44%

Unknown status2 · 22%

Terminated1 · 11%

Active, not recruiting1 · 11%

Suspended1 · 11%

Clinical Trials

Trial Activity

9 trials

HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Active, not recruiting·FFederal University of São Paulo·N/A·NCT04453436·2,500 enrolled

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

Completed·PPharmacia and Upjohn·N/A·NCT00002094

Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT02142751·161 enrolled

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00046033·118 enrolled

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance

Suspended·KKing Faisal University·N/A·NCT01132417·500 enrolled

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

Unknown status·QQianfoshan Hospital·N/A·NCT05850871·427 enrolled

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Unknown status·FFirst Hospital of Shijiazhuang City·Phase 2·NCT03765775·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)